Cargando…

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puglisi, Fabio, Gerratana, Lorenzo, Lambertini, Matteo, Ceppi, Marcello, Boni, Luca, Montemurro, Filippo, Russo, Stefania, Bighin, Claudia, De Laurentiis, Michelino, Giuliano, Mario, Bisagni, Giancarlo, Durando, Antonio, Turletti, Anna, Garrone, Ornella, Ardizzoni, Andrea, Gamucci, Teresa, Colantuoni, Giuseppe, Gravina, Adriano, De Placido, Sabino, Cognetti, Francesco, Del Mastro, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238951/ https://www.ncbi.nlm.nih.gov/pubmed/34183674 http://dx.doi.org/10.1038/s41523-021-00286-w

Ejemplares similares

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
por: Lambertini, Matteo, et al.
Publicado: (2023)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
por: Di Maio, Massimo, et al.
Publicado: (2023)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
por: De Angelis, Carmine, et al.
Publicado: (2017)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
por: Lunardi, G., et al.
Publicado: (2012)

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
por: Del Mastro, Lucia, et al.
Publicado: (2013)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study
por: Blondeaux, Eva, et al.
Publicado: (2020)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review
por: Garutti, Mattia, et al.
Publicado: (2022)

Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study
por: Blondeaux, Eva, et al.
Publicado: (2020)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study
por: Bighin, Claudia, et al.
Publicado: (2017)

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project
por: Pelizzari, Giacomo, et al.
Publicado: (2018)

HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients
por: Del Mastro, L, et al.
Publicado: (2005)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Management of young women with early breast cancer
por: Poggio, Francesca, et al.
Publicado: (2018)

The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer
por: Blondeaux, Eva, et al.
Publicado: (2021)

Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole
por: Sini, V, et al.
Publicado: (2014)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Rare tumours of the breast
por: Esposito, Emanuela, et al.
Publicado: (2019)

Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
por: Poggio, Francesca, et al.
Publicado: (2019)

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review
por: Di Lauro, V., et al.
Publicado: (2022)

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
por: Conte, PierFranco, et al.
Publicado: (2023)

Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging Technologies
por: Cucciniello, Linda, et al.
Publicado: (2022)

Guillain-Barre Syndrome Associated with Gastric Cancer: Paraneoplastic Syndrome or Immunological Disorder?
por: Colantuoni, Maria, et al.
Publicado: (2010)

Multigene tests for breast cancer: the physician’s perspective
por: Cognetti, Francesco, et al.
Publicado: (2021)

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
por: Arpino, Grazia, et al.
Publicado: (2015)

Male Breast Cancer: From Molecular Genetics to Clinical Management
por: Pensabene, Matilde, et al.
Publicado: (2022)

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
por: Giuliano, Mario, et al.
Publicado: (2011)

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Poggio, Francesca, et al.
Publicado: (2018)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
por: Untch, Michael, et al.
Publicado: (2021)

Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
por: Cancello, Giuseppe, et al.
Publicado: (2008)

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer
por: Licata, Luca, et al.
Publicado: (2023)

Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis
por: Bonardi, Benedetta, et al.
Publicado: (2020)

Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
por: Caputo, Roberta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6prg94ojguttpfqgb70mab7sp1